Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 26, 2021 at 04:15 am EDT
Share
Jafron Biomedical Co.,Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 1,781.81 million compared to CNY 1,315.33 million a year ago. Revenue was CNY 1,781.81 million compared to CNY 1,315.33 million a year ago. Net income was CNY 863.09 million compared to CNY 627.41 million a year ago. Basic earnings per share from continuing operations was CNY 1.08 compared to CNY 0.79 a year ago. Diluted earnings per share from continuing operations was CNY 1.07 compared to CNY 0.78 a year ago.
Jafron Biomedical Co.,Ltd. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Companyâs products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Companyâs products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Companyâs products are applied in 31 provinces, more than 3000 hospitals in China.